(Q38644858)

PubMed publication ID

28770976

5 September 2017

title

Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6460508&resulttype=core&format=json

13 May 2020

0 references

1 reference

Tess E Cooper

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6460508&resulttype=core&format=json

13 May 2020

Emma Fisher

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6460508&resulttype=core&format=json

13 May 2020

Nick Mr Wilkinson

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6460508&resulttype=core&format=json

13 May 2020

publication date

2 August 2017

1 reference

PubMed publication ID

28770976

Cochrane Database of Systematic Reviews

5 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6460508&resulttype=core&format=json

13 May 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6460508&resulttype=core&format=json

13 May 2020

page(s)

CD012537

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6460508&resulttype=core&format=json

A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results

13 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

Treatment of childhood hypophosphatasia with nonsteroidal antiinflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

A comprehensive categorical and bibliometric analysis of published research articles on pediatric pain from 1975 to 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

The role of the immune system in the generation of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

Opioids for chronic non-cancer pain in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

Antidepressants for chronic non-cancer pain in children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

Non-steroidal anti-inflammatory drugs (NSAIDs) for cancer-related pain in children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

Paracetamol (acetaminophen) for chronic non-cancer pain in children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

Influence of trial sample size on treatment effect estimates: meta-epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

Association between analytic strategy and estimates of treatment outcomes in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

Managing chronic pain in children and adolescents. We need to address the embarrassing lack of data for this common problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

Further characterization of a rat model of varicella zoster virus-associated pain: Relationship between mechanical hypersensitivity and anxiety-related behavior, and the influence of analgesic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

Epidural injection of cyclooxygenase-2 inhibitor attenuates pain-related behavior following application of nucleus pulposus to the nerve root in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

Meta-analysis in clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

An assessment of the safety of pediatric ibuprofen. A practitioner-based randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

Renal function after short-term ibuprofen use in infants and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

The safety of acetaminophen and ibuprofen among children younger than two years old.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

Nonsteroidal anti-inflammatory drugs are an important cause of acute kidney injury in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

Pregabalin for acute and chronic pain in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

"Evidence" in chronic pain--establishing best practice in the reporting of systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

Fibromyalgia: Moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

Clinical effectiveness: an approach to clinical trial design more relevant to clinical practice, acknowledging the importance of individual differences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

Mean analgesic consumption is inappropriate for testing analgesic efficacy in post-operative pain: analysis and alternative suggestion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

Expect analgesic failure; pursue analgesic success

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

Duloxetine use in chronic painful conditions--individual patient data responder analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

Core outcome domains and measures for pediatric acute and chronic/recurrent pain clinical trials: PedIMMPACT recommendations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

Systematic review of the psychometric properties, interpretability and feasibility of self-report pain intensity measures for use in clinical trials in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

Pregabalin in fibromyalgia--responder analysis from individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis--a simulation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

Non-steroidal anti-inflammatory drugs for neuropathic pain: how do we explain continued widespread use?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

Systematic review of observational (behavioral) measures of pain for children and adolescents aged 3 to 18 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

Opioids for cancer-related pain in children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

Antiepileptic drugs for chronic non-cancer pain in children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012537.PUB2

Azapropazone versus indomethacin in a double blind test with patients with ankylosing spondylitis

21 January 2018

1 reference

12 December 2020

Tofranil in the treatment of low back pain

1 reference

12 December 2020

Ibuprofen suspension in the treatment of juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group

1 reference

12 December 2020

A prospective study comparing celecoxib with naproxen in children with juvenile rheumatoid arthritis

1 reference

12 December 2020

A double-blind comparative study of the analgesic effects of fenbufen, codeine, aspirin, propoxyphene and placebo

1 reference

12 December 2020

Aspirin and fenoprofen (Nalfon) in the treatment of juvenile rheumatoid arthritis results of the double blind-trial. A segment II study.

1 reference

12 December 2020

Hypersensitivity to Nonsteroidal Anti-inflammatory Drugs in Children and Adolescents: Cross-Intolerance Reactions

1 reference

12 December 2020

Double-blind study of ketoprofen and indomethacin in juvenile chronic arthritis

1 reference

12 December 2020

Numbers-needed-to-treat analyses--do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo-controlled chronic low back pain trials

1 reference

12 December 2020

Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension

1 reference

12 December 2020

Results of the treatment of juvenile rheumatoid arthritis with indomethacine

1 reference

12 December 2020

Morning stiffness and nightime pain in ankylosing spondylitis. A comparison between enteric-coated and plain naproxen tablets

1 reference

12 December 2020

Patient-centered perspective on treatment outcomes in chronic pain

1 reference

12 December 2020

10.1002/14651858.CD012537.PUB2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6460508&resulttype=core&format=json

13 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6460508&resulttype=core&format=json

13 May 2020

PubMed publication ID

28770976

1 reference